false
0001130598
0001130598
2026-11-16
2026-11-16
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
November 16, 2026
Traws
Pharma, Inc.
(Exact name of Registrant as specified in its
charter)
| Delaware |
|
001-36020 |
|
22-3627252 |
(State or Other Jurisdiction
of Incorporation or Organization) |
|
(Commission
File Number) |
|
(I.R.S. Employer
Identification No.) |
12 Penns Trail
Newtown, PA 18940 |
| (267)
759-3680 |
(Address,
Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)
Not Applicable
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
| Common
stock, par value $.01 per share |
TRAW |
The
Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item
2.02 Results of Operations and Financial Condition.
The information provided below in “Item
7.01 - Regulation FD Disclosure” of this Current Report on Form 8-K (this “Current Report”) regarding the Earnings
Release is incorporated by reference into this Item 2.02.
Item 7.01 Regulation FD Disclosure.
On November 16, 2026, Traws Pharma, Inc.
(the “Company”) issued a press release (the “Earnings Release”) announcing its financial results for the quarter
ended September 30, 2026, a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the “Current
Report”) and incorporated herein by reference.
The information set forth under
Item 7.01 of this Current Report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject
to the liabilities of such section. The information in Item 7.01 of this Current Report, including Exhibit 99.1, shall not be incorporated
by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference
language in any such filing, except as expressly set forth by specific reference in such a filing. This Current Report will not be deemed
an admission as to the materiality of any information in this Current Report that is required to be disclosed solely by Regulation FD.
Forward-Looking Statements
This Current Report, including
Exhibit 99.1, contains certain forward-looking statements that involve substantial risks and uncertainties. When used herein, the
terms “anticipates,” “expects,” “estimates,” “believes,” “will” and similar
expressions, as they relate to the Company or its management, are intended to identify such forward-looking statements.
Forward-looking statements in
this Current Report, including Exhibit 99.1, or hereafter, including in other publicly available documents filed with the Securities
and Exchange Commission, reports to the stockholders of the Company and other publicly available statements issued or released by the
Company involve known and unknown risks, uncertainties and other factors which could cause the Company’s actual results, performance
(financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed
or implied by such forward-looking statements. Such future results are based upon management’s best estimates based upon current
conditions and the most recent results of operations. These risks include, but are not limited to, the risks set forth herein and in such
other documents filed with the Securities and Exchange Commission, each of which could adversely affect the Company’s business and
the accuracy of the forward-looking statements contained herein.
Item 9.01 Financial
Statements and Exhibits.
(d) Exhibits.
| Exhibit No. |
|
Description |
| 99.1 |
|
Press Release, dated November 16, 2026 |
| 104 |
|
Cover Page Interactive Data File (embedded within the inline XBRL Document) |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
| Date: November 16, 2026 |
TRAWS PHARMA, INC. |
| |
|
|
| |
By: |
/s/ Charles Parker |
| |
|
Charles Parker |
| |
|
Chief Financial Officer |
Exhibit 99.1

Traws Pharma
Reports Third Quarter 2026 Financial Results and Provides Business Highlights
| · | Ratutrelvir (COVID): Positive final Phase 2a results support further studies in PAXLOVID®-ineligible
patients |
| · | Tivoxavir marboxil (TXM, Influenza): Successful completion of tablet bridging study and toxicology retesting support
a planned Q4 2026 regulatory resubmission |
NEWTOWN, PA, November 16, 2026 (GLOBE NEWSWIRE)
– Traws Pharma, Inc. (NASDAQ: TRAW, “Traws Pharma,” “Traws” or “the Company”), a clinical-stage
biopharmaceutical company developing novel therapies for COVID-19 and influenza, today reported financial results for the quarter ended
September 30, 2026, and provided business highlights for its two antiviral programs: ratutrelvir, a once-daily, ritonavir-free oral antiviral
in development for COVID-19, and tivoxavir marboxil (TXM), an investigational long-acting agent for the prevention of seasonal and pandemic
influenza.
“We have made meaningful progress toward
our goal of developing new treatment and prevention options for patients most vulnerable to serious respiratory viral diseases,”
said Iain Dukes, MA, DPhil, Chief Executive Officer of Traws Pharma. “For ratutrelvir, the final Phase 2a results support
its potential as a once-daily, ritonavir-free treatment option for COVID-19, particularly for patients who are ineligible for PAXLOVID®.
Our next priority is to engage the FDA on a registration strategy focused on these patients.”
“For tivoxavir marboxil, the tablet
bridging study achieved its objectives, and toxicology retesting is complete. These results support further evaluation of TXM as a potential
once-monthly oral influenza prevention option. We expect to resubmit the updated toxicology package in the fourth
quarter,” concluded Dr. Dukes.
Recent Business Highlights
Ratutrelvir:
| · | Positive Phase 2a results Support Potential as a Ritonavir-Free Treatment Option. The final 92-subject study showed symptom
resolution comparable to PAXLOVID®, with fewer treatment-related adverse events and no viral rebound through Day 28. Median
time to sustained symptom resolution of 13.5 days with ratutrelvir versus 14.5 days with PAXLOVID® in eligible subjects.
Treatment-related adverse events occurred in 1 of 32 ratutrelvir-treated patients versus 4 of 30 treated with PAXLOVID®.
In 30 PAXLOVID®-ineligible subjects, median symptom resolution was 14.0 days, with no treatment-related adverse events
reported . |
| · | Regulatory Planning for PAXLOVID®-Ineligible Patients. Traws intends to discuss with the U.S. Food and
Drug Administration (FDA) a registration strategy for adults at high risk of progression to severe COVID-19 who are ineligible for PAXLOVID®,
including a potential adaptive Phase 2b/Pivotal program and Fast Track designation. |
Tivoxavir Marboxil
| · | Promising New Compressed-Tablet Bridging Study Results. The compressed-tablet formulation provided exposure comparable to the
powder-in-capsule formulation and was well tolerated. Consistent with the Company’s earlier modeling, the tablet could support once-monthly
dosing. The Company believes the results also support TXM’s use in further efficacy studies, including a planned human influenza
challenge study. |
| · | TXM Toxicology Re-Testing Results Support Updated Regulatory Submissions. Two independent rat
Pig-a gene mutation studies showed no mutagenic effect at doses up to 500 mg/kg, representing an approximately 125-fold margin over planned
clinical exposure based on dose. Traws expects to resubmit the updated toxicology package to regulators in the fourth quarter of 2026 .
|
Corporate Update
| · | Entered into a $50 million common stock purchase agreement with Roth Principal Investments. Under the October 23, 2026 agreement,
Traws has the right, but not the obligation, to sell up to $50 million of its common stock to Roth, subject to customary conditions. No
shares have been sold under the agreement to date. |
Third Quarter 2026 Financial Results
| · | Cash and cash equivalents. $2.3 million as of September 30, 2026, compared with $3.8 million as of December 31, 2025. |
| · | Research and development expenses. $1.8 million for the third quarter of 2026, compared with $2.3 million for the third quarter
of 2025. |
| · | General and administrative expenses. $1.8 million for the third quarter of 2026, compared with $1.7 million for the third quarter
of 2025. |
| · | Net loss. $3.5 million for the third quarter of 2026, compared with $4.0 million for the third quarter of 2025. Net loss per
common share, basic and diluted, was $0.18 compared with $0.34 in the prior-year period. |
| · | Shares Outstanding:
Traws had 15,368,277 shares of common stock outstanding as of November 13, 2026. |
About Ratutrelvir
Ratutrelvir is an investigational oral, small
molecule Mpro (3CL protease) inhibitor designed to act broadly against SARS-CoV-2/COVID-19 strains without the need for ritonavir. It
has demonstrated in vitro activity against a range of virus strains. Industry data indicate that COVID treatment represents a potential
multi-billion dollar market opportunity1. Ratutrelvir has not been approved by any regulatory authority.
About Tivoxavir Marboxil
Tivoxavir marboxil (TXM) is an investigational
oral, small molecule CAP-dependent endonuclease inhibitor designed for single dose prevention of seasonal influenza and
bird flu. It has shown in vitro activity against a range of influenza strains in preclinical studies. Seasonal influenza represents an
estimated multi-billion-dollar antiviral market opportunity, largely driven by global health organizations, practice guidelines and government
tenders and inclusion in drug stock piling initiatives2,3, with upside potential from potential pandemic flu outbreaks including
H5N1 bird flu. TXM has not been approved by any regulatory authority.
About Traws Pharma, Inc.
Traws Pharma is a clinical-stage biopharmaceutical
company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. Traws integrates
antiviral drug development, medical intelligence and regulatory strategy to address real world challenges in the treatment of viral diseases.
The Company is advancing novel investigational oral small molecule antiviral designed to have potent activity against difficult-to-treat
or resistant virus strains. These include viruses associated with seasonal influenza and H5N1 bird flu, as well as negative-strand RNA
viruses including Hantavirus, Ebola Virus Disease, and Lassa Fever and viruses associated with COVID-19/Long COVID.
Source Information
| 1. | Pfizer Inc. annual report on Form 10-K for the fiscal year ended December
31, 2025, filed with the U.S. Securities and Exchange Commission on February 3, 2026 |
Third-party products mentioned herein are the
trademarks of their respective owners. PAXLOVID® is a registered trademark of Pfizer Inc.
Forward-Looking Statements
Some of the statements in this release are forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of
1934, as amended, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties including statements regarding
the Company, its business and product candidates, including the potential opportunity, market size, benefits, effectiveness, safety, and
the clinical and regulatory plans for ratutrelvir and tivoxavir marboxil, as well as plans for its legacy programs. The Company has attempted
to identify forward-looking statements by terminology including “believes”, “estimates”, “anticipates”,
“expects”, “plans”, “intends”, “may”, “could”, “might”, “will”,
“should”, “potential”, “preliminary”, “encouraging”, “approximately” or other
words that convey uncertainty of future events or outcomes. Although Traws believes that the expectations reflected in such forward-looking
statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or
implied by such forward looking statements. These statements are only predictions and involve known and unknown risks, uncertainties,
and other factors, including planned discussions with the FDA, potential Fast Track designation, the outcome of Traws’ IND filing
with the U.S. Food and Drug Administration (FDA) for tivoxavir marboxil, including the current FDA clinical hold; the success and timing
of Traws’ clinical trials; the potential for tivoxavir marboxil or ratutrelvir to gain market acceptance, if and when regulatory
approval is obtained, or to become the new standard of care; Traws’ interactions with the FDA, Biomedical Advanced Research and
Development Authority (BARDA) and similar foreign regulators; collaborations; market conditions; regulatory requirements and pathways
for approval; the extent of the spread and threat of the bird flu; COVID-19; seasonal flu; the Company’s cash projections; Traws’
ability to raise additional capital when needed; and those discussed under the heading “Risk Factors” in Traws’ filings
with the U.S. Securities and Exchange Commission (SEC). Any forward-looking statements contained in this release speak only as of its
date. Traws undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances
occurring after its date or to reflect the occurrence of unanticipated events, except to the extent required by law.
Contacts
Traws Pharma Contact:
Charles Parker
Traws Pharma, Inc.
cparker@trawspharma.com
www.trawspharma.com
Investor Contact:
John Fraunces
LifeSci Advisors, LLC
917-355-2395
jfraunces@lifesciadvisors.com
Traws Pharma, Inc.
Condensed Consolidated Statements of Operations (unaudited)
| | |
Three Months Ended September 30, | | |
Nine Months Ended September 30, | |
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| Revenue | |
$ | — | | |
$ | — | | |
$ | — | | |
$ | 2,790,000 | |
| Operating expenses (income): | |
| | | |
| | | |
| | | |
| | |
| Research and development | |
| 1,832,000 | | |
| 2,311,000 | | |
| 9,037,000 | | |
| 7,108,000 | |
| General and administrative | |
| 1,770,000 | | |
| 1,744,000 | | |
| 7,283,000 | | |
| 6,189,000 | |
| Other operating income | |
| — | | |
| — | | |
| (1,405,000 | ) | |
| — | |
| Total operating expenses, net | |
| 3,602,000 | | |
| 4,055,000 | | |
| 14,915,000 | | |
| 13,297,000 | |
| Loss from operations | |
| (3,602,000 | ) | |
| (4,055,000 | ) | |
| (14,915,000 | ) | |
| (10,507,000 | ) |
| Change in fair value of warrant liability | |
| 37,000 | | |
| (3,000 | ) | |
| 93,000 | | |
| 26,656,000 | |
| Other income (loss), net | |
| 18,000 | | |
| 96,000 | | |
| (42,000 | ) | |
| 464,000 | |
| Net (loss) income | |
$ | (3,547,000 | ) | |
$ | (3,962,000 | ) | |
$ | (14,864,000 | ) | |
$ | 16,613,000 | |
| Net (loss) income attributable to common stockholders, basic and diluted | |
$ | (3,063,000 | ) | |
$ | (3,035,000 | ) | |
$ | (12,540,000 | ) | |
$ | 12,263,000 | |
| Weighted-average shares of common stock outstanding, basic | |
| 17,044,826 | | |
| 8,818,859 | | |
| 14,539,956 | | |
| 7,851,515 | |
| Net (loss) income per share of common stock, basic | |
$ | (0.18 | ) | |
$ | (0.34 | ) | |
$ | (0.86 | ) | |
$ | 1.56 | |
| Weighted-average shares of common stock outstanding, diluted | |
| 17,044,826 | | |
| 8,818,859 | | |
| 14,539,956 | | |
| 8,006,487 | |
| Net (loss) income per share of common stock, diluted | |
$ | (0.18 | ) | |
$ | (0.34 | ) | |
$ | (0.86 | ) | |
$ | 1.53 | |
| Net (loss) income attributable to Series C Preferred stockholders, basic and diluted | |
$ | (484,000 | ) | |
$ | (927,000 | ) | |
$ | (2,324,000 | ) | |
$ | 4,350,000 | |
| Weighted-average shares of Series C Preferred outstanding, basic and diluted | |
| 6,737 | | |
| 6,737 | | |
| 6,737 | | |
| 6,962 | |
| Net (loss) income per share of Series C Preferred, basic and diluted | |
$ | (71.84 | ) | |
$ | (137.60 | ) | |
$ | (344.96 | ) | |
$ | 624.82 | |
Traws Pharma, Inc.
Condensed Consolidated Balance Sheets (unaudited)
| | |
September 30, | | |
December 31, | |
| | |
2026 | | |
2025 | |
| Assets | |
| | | |
| | |
| Current assets: | |
| | | |
| | |
| Cash and cash equivalents | |
$ | 2,338,000 | | |
$ | 3,820,000 | |
| Tax incentive and other receivables | |
| 2,195,000 | | |
| 3,794,000 | |
| Prepaid expenses and other assets | |
| 444,000 | | |
| 365,000 | |
| Total current assets | |
| 4,977,000 | | |
| 7,979,000 | |
| Property and equipment, net | |
| 5,000 | | |
| 7,000 | |
| Intangible assets, net | |
| 2,398,000 | | |
| 2,527,000 | |
| Other assets | |
| 142,000 | | |
| 104,000 | |
| Total assets | |
$ | 7,522,000 | | |
$ | 10,617,000 | |
| Liabilities and stockholders’ deficit | |
| | | |
| | |
| Current liabilities: | |
| | | |
| | |
| Accounts payable | |
$ | 6,651,000 | | |
$ | 5,653,000 | |
| Accrued expenses and other liabilities | |
| 2,991,000 | | |
| 5,493,000 | |
| Total current liabilities | |
| 9,642,000 | | |
| 11,146,000 | |
| Warrant liabilities | |
| 8,000 | | |
| 100,000 | |
| Total liabilities | |
| 9,650,000 | | |
| 11,246,000 | |
| | |
| | | |
| | |
| Commitments and contingencies (Note 5) | |
| | | |
| | |
| | |
| | | |
| | |
| Stockholders’ deficit: | |
| | | |
| | |
| Series C Preferred stock, $0.01 par value, 5,000,000 shares authorized, 7,440 shares issued and 6,737 shares outstanding at September 30, 2026 and December 31, 2025 | |
| — | | |
| — | |
| Common stock, $0.01 par value, 250,000,000 shares authorized, 15,375,595 and 9,067,774 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively | |
| 153,000 | | |
| 90,000 | |
| Additional paid-in capital | |
| 652,574,000 | | |
| 639,259,000 | |
| Accumulated deficit | |
| (654,848,000 | ) | |
| (639,984,000 | ) |
| Accumulated other comprehensive (loss) income | |
| (7,000 | ) | |
| 6,000 | |
| Total stockholders’ deficit | |
| (2,128,000 | ) | |
| (629,000 | ) |
| Total liabilities and stockholders’ deficit | |
$ | 7,522,000 | | |
$ | 10,617,000 | |